Saint Louis University Researchers Identify a Biomarker for Severe Liver Disease in Infants
ST. LOUIS — In a new study, Saint Louis University School of Medicine researchers and colleagues have identified biomarkers in high-risk infants with alpha-1 antitrypsin deficiency (AATD). This is a condition that is life-threatening in some infants but very mild in others. For the first time, predicting which children need lifesaving intervention is possible.
This latest advance follows the discovery of the first possible treatment for adults with AATD by SLU scientists and a Takeda Inc. team in 2022, bringing us nearer to the day when liver transplants are no longer required to treat rare liver disease.
Jeffrey Teckman, M.D., professor of pediatrics and biochemistry and molecular biology, in his lab at the Doisy Research Center on April 11, 2023. Photo by Sarah Conroy.
The findings, which recently appeared in Gastro Hep Advances, suggest that circulating Z polymer levels serve as a biomarker for those with AATD who are likely to develop severe liver disease.
“These data will allow identification of a group of infants at high risk of severe disease soon after diagnosis,” said Jeffrey Teckman, M.D., professor of pediatrics and biochemistry and molecular biology at Saint Louis University.
Teckman is the paper's senior author. He is a leading authority on AATD, a genetic disease that affects one in 3,500 people and has over 100 variants, including ZZ genotypes that increase the risk for lung and liver disease in adults and children.
Symptoms may include shortness of breath and wheezing, repeated infections of the lungs, yellow skin, fatigue, cirrhosis, clinically evident portal hypertension (CEPH), liver failure and even death. Other than a liver transplant, Teckman says there is currently no treatment for AATD.
Scientists have made significant progress in developing new therapies for AATD in recent years, though none are yet approved. While many adult clinical trials enroll participants, none study infants or children. The newly identified biomarkers in infants will stimulate and accelerate future pediatric clinical trials associated with high-risk infants.
“Enrollment of children into trials can then be focused on this high-risk group, sparing many participants from needless trials and speeding the effective treatments to proof of efficacy and approval,” said Teckman, who is also director of pediatric gastroenterology and hepatology at SLU.
The data was collected by the Childhood Liver Disease Research Network (ChiLDReN), a National Institutes of Health (NIH)-supported consortium of pediatric tertiary care centers in North America.
Seventeen consortium centers collected data during the study period, focusing on pediatric liver diseases and aiming to describe the natural history and genetic and environmental modifiers of a group of metabolic-cholestatic liver diseases, including AATD. Researchers measured ZZ AAT serum polymer levels from prospectively collected samples from participants in the Longitudinal Observational Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC) and compared their outcomes in the longitudinal database.
Keith Blomenkamp, senior research assistant in Jeffrey Teckman’s lab, co-authored the paper and is shown here at the Doisy Research Center on April 11, 2023. Photo by Sarah Conroy.
Teckman and his colleagues obtained data and samples to identify biomarkers predictive of severe AATD liver disease. They analyzed prospective AATD ChiLDReN data and serum samples from 251 individuals from 2007-2015 for outcomes and Z polymer levels. Researchers found that 58 of 251 had CEPH at enrollment, and 10 developed CEPH during follow-up. Higher Z AAT polymer levels were associated with existing CEPH. In infants without CEPH, higher polymer levels were related to future CEPH later in childhood, but total AAT was not predictive. In the first few months of life, gamma-glutamyl transpeptidase (GGT), an enzyme found throughout the body, particularly in the liver, was also significantly associated with future CEPH.
Teckman and his colleagues constructed a model identifying subjects at high risk of future CEPH by combining clinical GGT and polymer levels. High circulating Z polymer levels and high GGT early in life are associated with future CEPH in AATD.
Additional authors of the paper include Paula Buchanan, Ph.D., Department of Health and Clinical Outcomes Research, Saint Louis University School of Medicine; Keith Steven Blomenkamp, Departments of Pediatrics and Biochemistry and Molecular Biology, Saint Louis University School of Medicine, SSM Health Cardinal Glennon Children's Hospital; Keith Burling, Core Biochemical Assay Laboratory, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Nina Heyer-Chauhan, Ph.D., UCL Respiratory, Division of Medicine, University College London; and David A Lomas, Ph.D., UCL Respiratory, Division of Medicine, University College London.
Teckman is supported by the ChiLDReN: NIH: DK 62453 and UL1 TR002535 (University of Colorado Denver, Children’s Hospital Colorado, subcontracts), Alpha-1 Foundation, Saint Louis University Liver Center, Cardinal Glennon Children’s Hospital Foundation.
Lomas is supported by the Medical Research Council (UK) (MR/NO24842/1 and MR/V034243/1), the Alpha-1 Foundation (USA), Alpha-1 Awareness and the NIHR UCLH Biomedical Research Centre. He is an NIHR Senior Investigator. University of Michigan, Sample and Data Coordinating Center; NIH-DK062456 (collection and distribution of biosamples and data).
Latest Newslink
- Achieves Prestigious R1 Status, Joining Elite Group of U.S. Research UniversitiesR1 designation is the highest classification that universities can attain for research activity. SLU’s rise to R1 is the result of a decade-long, institution-wide effort to become a national exemplar for educational and research excellence. Since 2014, the University has focused on creating a robust research environment that fosters collaboration across disciplines and offers new opportunities for faculty and students to explore today’s most urgent challenges.
- Six SLU Students Advance to Semifinalist Stage for Fulbright GrantsSaint Louis University's Office of Competitive Fellowships and Scholarships has announced that six SLU students have been selected as semifinalists for the prestigious Fulbright U.S. Student Program. Fulbright decisions are updated regularly, and applicants will be notified in the spring whether they have been selected as finalists to receive the award.
- Tickets to See Colson Whitehead Receive 2025 St. Louis Literary Award Go on Sale on February 7Tickets for the St. Louis Literary Award ceremony honoring Pulitzer Prize-winning author Colson Whitehead will go on sale Friday, Feb. 7, at 10 a.m. Whitehead will receive the award on April 9 at the Sheldon Concert Hall. Tickets for the 2025 St. Louis Literary Award event are $15 and available through Metrotix.
- Second SLU Golf and Give Challenge Set for February 25-26The Saint Louis University community is invited to chip in and stock the Billiken Bounty food pantry by playing miniature golf holes created by SLU students. The innovation challenge is led by SLU's School of Science and Engineering and Chaifetz Center for Entrepreneurship.
- Chaifetz Center for Entrepreneurship Accepting Applications for Second New Venture Accelerator CohortAfter a successful first year, Saint Louis University’s Chaifetz Center for Entrepreneurship is opening up applications for its second New Venture Accelerator (NVA). The NVA, which offers students and young alumni an opportunity to launch their businesses with financial support, resources, and mentoring from SLU experts, launched in 2024 with an initial cohort of four businesses.
- Annual Martin Luther King Jr. Tribute Speakers Urge HopefulnessTaking action and working to improve life was a common theme at the Martin Luther King Jr. Memorial Tribute ceremony on Thursday morning. SLU and St. Louis community members gathered in the St. Louis Room of the Busch Student Center for the annual event, a partnership between SLU and the Urban League of Metropolitan St. Louis, to remember and honor King.